2013
Characteristics Associated With Discontinuation of Long-Acting Reversible Contraception Within the First 6 Months of Use
Grunloh D, Casner T, Secura G, Peipert J, Madden T. Characteristics Associated With Discontinuation of Long-Acting Reversible Contraception Within the First 6 Months of Use. Obstetrics And Gynecology 2013, 122: 1214-1221. PMID: 24201685, PMCID: PMC4051392, DOI: 10.1097/01.aog.0000435452.86108.59.Peer-Reviewed Original ResearchConceptsLevonorgestrel intrauterine systemIntrauterine deviceEarly discontinuationCopper intrauterine deviceBaseline characteristicsIntrauterine systemReversible contraceptionFirst-line contraceptive optionRate of discontinuationLong-Acting Reversible ContraceptionLow socioeconomic statusContraceptive CHOICE ProjectMonths of useCohort studyDiscontinuation ratesContraceptive optionsUnintended pregnancyFrequent bleedingDiscontinuationIUD usersCost contraceptionCommon reasonYounger ageLogistic regressionTelephone interviews
2011
Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial
Madden T, Proehl S, Allsworth J, Secura G, Peipert J. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. American Journal Of Obstetrics And Gynecology 2011, 206: 129.e1-129.e8. PMID: 22055339, PMCID: PMC3268863, DOI: 10.1016/j.ajog.2011.09.021.Peer-Reviewed Original ResearchConceptsNaproxen groupIntrauterine systemLevonorgestrel-releasing intrauterine system useLevonorgestrel-releasing intrauterine systemAdministration of naproxenLevonorgestrel intrauterine systemIntrauterine system useOral naproxenEstradiol groupTreat analysisMultivariable analysisLowest quartileFrequent bleedingPlaceboEstradiol decreaseEstradiolTrialsWomenNaproxenDaysGroupBleedingQuartileAdministrationWeeks